Metformin is a drug used to treat patients with type 2 diabetes, especially those who suffer from obesity. It is also used in treating women with polycystic ovary syndrome (PCOS). This disease has been shown to be related to insulin resistance and multiplied blood sugar ranges. Further, it has been found that using metformin improves these women's menstrual cycles and ovulation rates. Methods: A structured questionnaire will be conducted to determine the prevalence of breast cancer among women using metformin in the Hail region. Result: The incidence of breast cancer among women using metformin in the Hail region is very low. Conclusions: According to previous findings, metformin has been linked to lower breast cancer risk in women with type 2 diabetes. Furthermore, the findings of this study have corroborated the literature for the same by indicating a substantial connection between metformin use and a lower risk of breast cancer in women with type 2 diabetes.